DK3713572T3 - Behandling af takykardi - Google Patents
Behandling af takykardiInfo
- Publication number
- DK3713572T3 DK3713572T3 DK18804633.8T DK18804633T DK3713572T3 DK 3713572 T3 DK3713572 T3 DK 3713572T3 DK 18804633 T DK18804633 T DK 18804633T DK 3713572 T3 DK3713572 T3 DK 3713572T3
- Authority
- DK
- Denmark
- Prior art keywords
- tachycardia
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17203377 | 2017-11-23 | ||
| PCT/EP2018/082450 WO2019101970A1 (en) | 2017-11-23 | 2018-11-23 | Treatment of tachycardia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3713572T3 true DK3713572T3 (da) | 2025-08-25 |
Family
ID=60452486
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18804633.8T DK3713572T3 (da) | 2017-11-23 | 2018-11-23 | Behandling af takykardi |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US11419874B2 (enExample) |
| EP (1) | EP3713572B1 (enExample) |
| JP (2) | JP2021504466A (enExample) |
| CN (1) | CN111447930A (enExample) |
| AU (1) | AU2018371216B2 (enExample) |
| CA (1) | CA3083176A1 (enExample) |
| DK (1) | DK3713572T3 (enExample) |
| ES (1) | ES3039584T3 (enExample) |
| FI (1) | FI3713572T3 (enExample) |
| PL (1) | PL3713572T3 (enExample) |
| PT (1) | PT3713572T (enExample) |
| WO (1) | WO2019101970A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11219642B1 (en) * | 2020-09-01 | 2022-01-11 | Catherine Lueninghoener | Methods and compositions for treating heart conditions |
| CN113063804B (zh) * | 2021-03-16 | 2022-07-15 | 太原科技大学 | 一种基于图像处理的热切机视觉系统自动定位方法 |
| TWI827037B (zh) * | 2021-05-07 | 2023-12-21 | 美商默沙東有限責任公司 | 作為nav1.8抑制劑之環烷基3-側氧基哌甲醯胺及環雜烷基3-側氧基哌甲醯胺 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10064105A1 (de) | 2000-12-21 | 2002-06-27 | Bayer Ag | Neue Substituierte Imidazotriazinone |
| NZ540167A (en) | 2002-10-30 | 2007-06-29 | Neuro3D | Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| EP1601675A1 (en) * | 2003-03-04 | 2005-12-07 | ALTANA Pharma AG | Purin-6-one-derivatives |
| JP2007504117A (ja) | 2003-08-28 | 2007-03-01 | アルタナ ファルマ アクチエンゲゼルシャフト | 肺サーファクタントとｐｄｅ２阻害剤とを含有する組成物 |
| WO2005035505A2 (en) | 2003-09-30 | 2005-04-21 | Artesian Therapeutics, Inc. | Compounds with phosphodiesterase inhibiting and calcium channel blocking activities |
| WO2005041957A1 (en) | 2003-10-29 | 2005-05-12 | Pfizer Products Inc. | Oxindole derivatives and their use as phosphodiesterase type 2 inhibitors |
| DK1697356T3 (da) | 2003-12-16 | 2009-01-12 | Pfizer Prod Inc | Pyrido[2,3-d]pyrimidin-2,4-diaminer som PDE 2-inhibitorer |
| EP1548011A1 (en) | 2003-12-23 | 2005-06-29 | Neuro3D | Benzo[1,4]diazepin-2-one derivatives as phosphodiesterase PDE2 inhibitors, preparation and therapeutic use thereof |
| DE602005021894D1 (de) * | 2004-09-02 | 2010-07-29 | Nycomed Gmbh | Triazolophthalazine |
| EA012505B1 (ru) | 2005-01-05 | 2009-10-30 | Никомед Гмбх | Триазолофталазины в качестве ингибиторов pde-2 |
| JP5130053B2 (ja) | 2005-01-05 | 2013-01-30 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | トリアゾロフタラジン |
| EP1749824A1 (en) | 2005-08-03 | 2007-02-07 | Neuro3D | Benzodiazepine derivatives, their preparation and the therapeutic use thereof |
| DE102006048693A1 (de) | 2006-10-14 | 2008-04-17 | Bayer Healthcare Ag | Inhibition der PDE2A |
| US20110190373A1 (en) * | 2008-05-05 | 2011-08-04 | University Of Rochester | Methods and compositions for the treatment or prevention of pathological cardiac remodeling and heart failure |
| WO2010054253A1 (en) | 2008-11-07 | 2010-05-14 | Biotie Therapies Gmbh | Triazine derivatives as inhibitors of phosphodiesterases |
| US9540379B2 (en) | 2011-01-31 | 2017-01-10 | Boehringer Ingelheim International Gmbh | (1,2,4)triazolo[4,3-A]quinoxaline derivatives as inhibitors of phosphodiesterases |
| WO2012114222A1 (en) | 2011-02-23 | 2012-08-30 | Pfizer Inc. | IMIDAZO[5,1-f][1,2,4]TRIAZINES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS |
| EP2718295A1 (en) | 2011-06-07 | 2014-04-16 | Pfizer Inc | Pyrazolo[3,4-d]pyrimidine compounds and their use as pde2 inhibitors and/or cyp3a4 inhibitors |
| ES2575092T3 (es) | 2011-06-27 | 2016-06-24 | Janssen Pharmaceutica, N.V. | Derivados de 1-aril-4-metil-[1,2,4]triazolo[4,3-a]quinoxalina |
| MX361539B (es) | 2012-04-25 | 2018-12-10 | Takeda Pharmaceuticals Co | Compuesto heterociclico nitrogenado. |
| WO2014010732A1 (ja) | 2012-07-13 | 2014-01-16 | 武田薬品工業株式会社 | 複素環化合物 |
| US20140045856A1 (en) | 2012-07-31 | 2014-02-13 | Boehringer Ingelheim International Gmbh | 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes |
| EP3026051A4 (en) | 2013-07-24 | 2017-03-08 | Takeda Pharmaceutical Company Limited | Heterocyclic compound |
| JP2017114764A (ja) * | 2014-04-25 | 2017-06-29 | 武田薬品工業株式会社 | 片頭痛治療剤 |
| TWI568737B (zh) | 2014-11-05 | 2017-02-01 | 達特神經科學（開曼）有限責任公司 | 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物 |
-
2018
- 2018-11-23 JP JP2020545878A patent/JP2021504466A/ja active Pending
- 2018-11-23 US US16/766,388 patent/US11419874B2/en active Active
- 2018-11-23 CN CN201880078272.XA patent/CN111447930A/zh active Pending
- 2018-11-23 CA CA3083176A patent/CA3083176A1/en active Pending
- 2018-11-23 EP EP18804633.8A patent/EP3713572B1/en active Active
- 2018-11-23 DK DK18804633.8T patent/DK3713572T3/da active
- 2018-11-23 FI FIEP18804633.8T patent/FI3713572T3/fi active
- 2018-11-23 ES ES18804633T patent/ES3039584T3/es active Active
- 2018-11-23 WO PCT/EP2018/082450 patent/WO2019101970A1/en not_active Ceased
- 2018-11-23 PT PT188046338T patent/PT3713572T/pt unknown
- 2018-11-23 AU AU2018371216A patent/AU2018371216B2/en active Active
- 2018-11-23 PL PL18804633.8T patent/PL3713572T3/pl unknown
-
2022
- 2022-07-18 US US17/866,795 patent/US20220362251A1/en not_active Abandoned
-
2023
- 2023-11-02 JP JP2023188086A patent/JP2024012483A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2018371216B2 (en) | 2024-09-19 |
| PT3713572T (pt) | 2025-08-28 |
| CN111447930A (zh) | 2020-07-24 |
| EP3713572B1 (en) | 2025-07-30 |
| JP2021504466A (ja) | 2021-02-15 |
| EP3713572A1 (en) | 2020-09-30 |
| US20220362251A1 (en) | 2022-11-17 |
| ES3039584T3 (en) | 2025-10-22 |
| AU2018371216A1 (en) | 2020-06-04 |
| WO2019101970A1 (en) | 2019-05-31 |
| US11419874B2 (en) | 2022-08-23 |
| CA3083176A1 (en) | 2019-05-31 |
| JP2024012483A (ja) | 2024-01-30 |
| FI3713572T3 (fi) | 2025-09-09 |
| PL3713572T3 (pl) | 2025-09-22 |
| US20200345744A1 (en) | 2020-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3851537T5 (da) | Behandling af hyperbilirubinæmi | |
| PL3265053T3 (pl) | Sposoby leczenia skóry | |
| EP3601536A4 (en) | TREATMENT PROCESSES | |
| IL263680A (en) | Combination therapies | |
| EP3420388A4 (en) | PUPILS EQUALIZATION | |
| DK3504187T3 (da) | Anvendelse af pridopidin til behandling af funktionel tilbagegang | |
| HUE056287T2 (hu) | Pancreatitis kezelése | |
| EP3324961C0 (en) | TREATMENT OF ANGELMAN SYNDROME WITH GABOXADOL | |
| DK3362066T3 (da) | Kombinationsterapi til behandling af maligniteter | |
| DK3506904T3 (da) | Behandling af demens | |
| DK3390390T3 (da) | Bipyrazolylderivater egnede til behandling af autoimmunsygdomme | |
| EP3406336A4 (en) | NANO FOIL OF CORE CASE STRUCTURE TYPE | |
| DK3458052T3 (da) | Kombinationsbehandling af cancer | |
| HUE050944T2 (hu) | Kezelési eljárás tradipitant alkalmazásával | |
| IL272851A (en) | Methods of using dipivefrin | |
| DK3307267T3 (da) | Behandling af multipel sklerose | |
| DK3283210T3 (da) | Fremgangsmåde | |
| PL3393468T3 (pl) | Metody leczenia niedoboru odporności | |
| DK3261661T3 (da) | Menotropin til behandling af infertilitet | |
| EP3597225A4 (en) | TREATMENT PROCESS | |
| DK3368044T3 (da) | Behandling af hepatisk steatose-relateret oligo-ovulation | |
| DK3297619T3 (da) | Terapeutiske anvendelser af L-4-chlorkynurenin | |
| DK3585808T3 (da) | Modificerede serpiner til behandlingen af bradykinin formidlet sygdom | |
| EP3493821A4 (en) | METHOD OF TREATING THE RESPIRATORY TRACT | |
| DK3484475T3 (da) | 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom |